Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

NanoString Technologies Inc (NSTGQ)NSTGQ

Upturn stock ratingUpturn stock rating
NanoString Technologies Inc
$0.07
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

06/25/2024: NSTGQ (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -76.71%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 14
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 06/25/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -76.71%
Avg. Invested days: 14
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/25/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -
Volume (30-day avg) 762921
Beta -
52 Weeks Range 0.04 - 5.18
Updated Date 06/6/2024
Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -
Volume (30-day avg) 762921
Beta -
52 Weeks Range 0.04 - 5.18
Updated Date 06/6/2024

Earnings Date

Report Date 2024-06-21
When AfterMarket
Estimate -1.24
Actual -
Report Date 2024-06-21
When AfterMarket
Estimate -1.24
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating -
Percent Insiders -
Percent Institutions -
Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating -
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating 4
Target Price -
Buy -
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Rating 4
Target Price -
Buy -
Strong Buy 1
Hold 1
Sell -
Strong Sell -

AI Summarization

NanoString Technologies Inc. (NASDAQ: NSTG)

Company Profile:

NanoString Technologies is a molecular diagnostics company that develops and sells innovative platforms and consumables for life science research and clinical diagnostics. The company's primary technology is the nCounter® Analysis System, a digital spatial profiling platform for analyzing gene expression and protein levels in single cells and tissues.

Top Products and Market Share:

  • nCounter Analysis System: This is NanoString's flagship product and holds a leading position in the spatial transcriptomics market. Its market share is estimated to be around 25% in this rapidly growing segment.
  • GeoMx® Digital Spatial Profiler (DSP): This platform enables researchers to perform spatial profiling at higher resolution and with increased multiplexing capabilities. It is a relatively new offering, and its market share is still developing.
  • CosMx Spatial Molecular Imager (SMI): This platform is specifically designed for clinical research and diagnostics. It is gaining traction in the field of precision oncology, where spatial profiling plays a crucial role in understanding tumor heterogeneity.

Financial Performance:

NanoString's revenue has grown steadily over the past few years, driven by the increasing adoption of its nCounter platform and the launch of new products like GeoMx and CosMx. The company reported revenue of $112.3 million in 2022, an increase of 22% year-over-year. However, NanoString is not yet profitable and continues to incur significant operating expenses related to research and development, marketing, and sales.

Growth Trajectory:

The market for spatial transcriptomics is expected to experience significant growth in the coming years, fueled by the increasing demand for personalized medicine and the need for better understanding of complex biological processes. NanoString is well-positioned to capitalize on this growth with its leading nCounter platform and expanding product portfolio.

Market Dynamics:

The spatial transcriptomics market is highly competitive, with several other companies developing similar technologies. Some of NanoString's key competitors include:

  • 10X Genomics (NASDAQ: TXG) - Market share: 20-25%
  • Illumina (NASDAQ: ILMN) - Market share: 15-20%
  • Bio-Rad Laboratories (NYSE: BIO) - Market share: 10-15%

Potential Challenges:

  • Competition: NanoString faces stiff competition from established players like Illumina and 10X Genomics with larger market share and resources.
  • Reimbursement: Obtaining reimbursement for its diagnostic products from major payers remains a key challenge.
  • Profitability: Reaching profitability remains elusive as research and development costs coupled with marketing expenses continue to weigh on margins.

Opportunities:

  • Expanding market: The spatial transcriptomics market is projected to grow significantly, creating ample opportunities for NanoString to expand its customer base.
  • New product launches: The launch of innovative products like GeoMx and CosMx opens up new avenues for growth in clinical research and diagnostics.
  • Strategic partnerships: Collaborations with pharmaceutical companies and research institutions could accelerate the adoption of NanoString's technologies.

Fundamental Rating based on AI: 7.5

The AI-based rating of 7.5 reflects NanoString's strong product portfolio, leading position in a rapidly growing market, and significant growth potential. However, the company's lack of profitability and intense competition remain concerns that temper the overall rating.

Justification:

  • Strengths:
    • Leading technology in the spatial transcriptomics market.
    • Diversifying product portfolio addressing different market segments.
    • Strong revenue growth driven by increasing adoption of its platforms.
  • Weaknesses:
    • Still not profitable and faces pressure on margins.
    • Intense competition from established players with larger resources.
    • Reimbursement challenges for its diagnostic products.

Overall, NanoString Technologies Inc. is a promising company with innovative technologies and a significant growth opportunity. However, investors should be aware of the company's challenges before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About NanoString Technologies Inc

Exchange NASDAQ Headquaters Seattle, WA, United States
IPO Launch date 2013-06-26 CEO, President & Director Mr. R. Bradley Gray
Sector Healthcare Website https://www.nanostring.com
Industry Medical Instruments & Supplies Full time employees 550
Headquaters Seattle, WA, United States
CEO, President & Director Mr. R. Bradley Gray
Website https://www.nanostring.com
Website https://www.nanostring.com
Full time employees 550

NS Wind Down Co., Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaborations with Lam Research Corporation and Parker Institute for Cancer Immunotherapy, Stanford Medicine, Acrobat Genomics, and Illumina Accelerator. The company was formerly known as NanoString Technologies, Inc. and changed its name to NS Wind Down Co., Inc. in May 2024. NS Wind Down Co., Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NS Wind Down Co., Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​